Walgreens Boots Alliance Inc. agreed to pay $269.2 million to settle two healthcare fraud lawsuits in the U.S., according to a Jan. 22 release from the U.S. Department of Justice.

The Illinois-based pharmacy chain was accused of improperly billing Medicare, Medicaid, and other federal healthcare programs for insulin pens that Walgreens "knowingly dispensed" to federal beneficiaries who did not need them. The company agreed to pay $209.2 million to resolve the claims.

In a separate case, Walgreens was accused of incorrectly charging Medicaid the lower drug prices that the retailer offered the public through a discount program. The company agreed to pay $60 million to settle the allegation.

"Overbilling and improper billing of Medicare and Medicaid unduly burden taxpayers and put the solvency of these vital healthcare programs at risk," Geoffrey Berman, the U.S. Attorney for the Southern District of New York, said in a statement.

The cases were filed by whistleblowers under the False Claims Act, according to the release. Walgreens admitted and accepted responsibility for both complaints, the statement added.